Medication Supported Recovery- A Review of Evidence-Based Practice
|
|
- Melanie George
- 5 years ago
- Views:
Transcription
1 Medication Supported Recovery- A Review of Evidence-Based Practice Andrew B. Mendenhall, MD, DABAM, DABFM, Senior Medical Director, Substance Use Disorder Services, Central City Concern 1
2 Objectives 1. Discuss the science and best-practices for the treatment of opioid use and alcohol use disorders. 2. Discuss historical barriers that exist within the treatment and recovery culture. 3. Review the stages of change and challenges in managing more of the SUD population. 4. Discuss the ideal model of care-integration to meet the needs of more of the SUDS population. 2
3 The Medical Literature 1. Supports the use of medication to help patients improve their probability of abstinence. Data has been around for nearly 50 years. Alcohol Use Disorders Opioid Use Disorders 2. Supports the attendance of fellowship groups as increasing the probability of sustained abstinence. Less than 15% of patients who attend 12-step meetings will continue to be active at 12 months. 90 meetings in 90 days is as effective as a 28 day residential treatment. Very poor outcomes data-self reported success rates of 80% or more 3
4 Oral Naltrexone and Alcohol Use Disorder
5 The Medical Literature 3. Demonstrates that treatment of Depressive Disorders markedly reduces substance use but have a minimal effect on the probability of total abstinence. 4. Informs clinicians that the disease of addiction is a chronic relapsing brain disease. Spectrum Disease- Mild, Moderate, Severe Vastly less expensive to treat than it is to ignore or to provide less effective treatment modalities. Edward V. Nunes, MD; Frances R. Levin, MD JAMA. 2004;291(15): doi: /jama
6 Slide from Dr. Darryl Inaba Pharm.D. CADC III
7 CEREBRAL ACTIVATION AND OPIOID CRAVNG Images Showing Differences in Activation of the Left Medial Prefrontal and Anterior Cingulate Cortex Between Response to a Drug-Related Audio-taped Script and to a Neutral Audio-taped Script in 12 Abstinent Opiate-Dependent Subjects Am J Psychiatry 158:10, Oct. 2001
8 CEREBRAL ACTIVATION AND OPIOID CRAVING Images Showing Activation in the Left Orbitofrontal Cortex Correlated With Scores on a Composite Crave/Urge Visual Analogue Scale for Eight Abstinent Opiate-Dependent Subjects. Am J Psychiatry 158:10, Oct. 2001
9 The History and Culture of Addiction Treatment 12-Step Fellowship has defined most of the culture of recovery for the past 80+ years Bill W. and Dr. Bob. AA, NA, HA, MA, OA, SAA Guiding principle of a spiritual transformation that occurs through fellowship and step-work. MILLIONS OF LIVES SAVED through this practice and culture. The Minnesota Model refers to the Hazelden-BettyFord Residential experience developed during the 1950s-1970s. Historically, the concept of taking any medication for any reason has been associated with not being abstinent. False belief that medication somehow impairs the possibility of spiritual transformation. 9
10 The History and Culture of Addiction Treatment 1969 The first Methadone programs opened in San Francisco, New York, Baltimore. Operated in relative silence and obscurity from the establishment form of drug and alcohol treatment s-1980 s Scientific Advances in understanding brain structure and function lead to clinical advances in treatment. Buprenorphine treatment access in the 1980 s in Europe s Addiction is Stigmatized: Crack Cocaine Epidemic Racial Injustice Industrialized, for-profit prisons 10
11 The History and Culture of Addiction Treatment DATA 2000/2004 Buprenorphine Access in the United States. Early 2000 s the Opioid Epidemic begins to declare itself Mental Health And Addiction Parity Act Clinical Access Deficiency to Evidence-Based Treatment Epidemic levels of Overdose and Death Criminal Justice systems practicing medicine. Persistent philosophical divide surrounding what works vs. what is best. 11
12 Patients Maintained with OAT Demonstrate VASTLY Less Relapse with Opioids. (OAT = Opioid Agonist Treatment)
13 What are the costs of caring for patients? (OAT = Opioid Agonist Treatment)
14 VAST Chasm between NEED and ACCESS Jones et. al. American Journal of Public Health, June 11 th,2015 Electronic Publication-Peer Reviewed. Jones et. al. American Journal of Public Health, June 11 th,2015 Electronic Publication-Peer Reviewed.
15 State-by-State Access Regression Analysis Jones et. al. American Journal of Public Health, June 11 th,2015 Jones et. Electronic al. American Publication-Peer Journal of Public Reviewed. Health, June 11 th,2015 Electronic Publication-Peer Reviewed.
16 Additional Challenges Low-quality MAT programs that do not hold patients accountable. Cash for buprenorphine programs. No Urine Monitoring Infrequent follow-up visits High-quality MAT programs that provide access to medication support in exchange for rigid standards around total abstinence. Stage-of-change mismatch Highest level of care first, then step-down Barriers to real-world engagement- like employment. Often abandon patients who are not successful. Blaming the patient who is not ready.
17 Additional Challenges Ok- I am a prescriber but I don t just want to prescribe. The patient needs treatment and Some Treatment Programs don t want MAT in their milieu Not Recovery Not Abstinence Vivitrol or Naltrexone is OK but Not Buprenorphine or Methadone Some Supportive Housing Environments don t want MAT in their milieu Same Allegations
18 Who to Care for and How to care for them? What segment of the SUD population are you capable of helping? Who can help you help more of the population? Who doesn t want to do anything differently? How can you work together to collaboratively care for more patients?
19 Severe SUD Patient Experience Crime Law Enforcement Employer Insurance Payer CJ/Restitution STOP Courts (MSR?) Sober Living (MSR?) Family Residential (MSR?) Drug Using Community Patient Outpatient Tx. (+/- MAT) ER/IC for Pills ER/IC for O.D. Deliver NAS Baby DETOX CTR Buprenorphine/V ivitrol Outpatient Admission to Hosp. Medical Admission for Psych. DEATH Methadone OTP
20 Medication support allows more patients to enter treatment: SUD= Substance use disorder -Treat earlier = Less Severe -Less impact on work and family -More outpatient, less inpatient
21 Defining Treatment Phases/Programming Stabilization for 3-6 months Maintenance for 6+ months Opioid positive Opioid negative + Impairment from other substances Opioid negative Early Recovery Use of substances without impairment Opioid negative With Rare use of ETOH or Cannabis Opioid negative And totally clean and sober It is critical to consider clinical stage of change and your program s threshold for management of a precontemplative patient population. This is particularly important considering cannabis and/or episodic alcohol use. It is ALSO critical to have an expedited pathway for clinical non-responders to Medication Support
22 A Fully Integrated Medical Home for Recovery A FULLY DEVELOPED SYSTEM: Accountable Care Organization Sober Housing ER Inpatient Day Tx Restitution Center (CJ) IC Clinic Medication Support from a Medical Clinic IOP OP OTP (methadone) and/or Suboxone Case Management/Recovery Management
23 Concluding Thoughts 1. What can you do to provide increased access to evidence-based practices for the treatment of substance use disorders? 2. What are the barriers that exist for you to successfully achieve the above? 3. Who can you ask for support and development of these services within your regional continuum? 23
24 THANK YOU Andy Mendenhall M.D. 24
The Role of Primary Care Teams and the Medical Neighborhood in Addressing the Opioid Crisis in Maine. March 10, 2016
The Role of Primary Care Teams and the Medical Neighborhood in Addressing the Opioid Crisis in Maine March 10, 2016 Objectives Review current state of opioid crisis in Maine Briefly review physiology of
More informationMedication-Assisted Treatment. What Is It and Why Do We Use It?
Medication-Assisted Treatment What Is It and Why Do We Use It? What is addiction, really? o The four C s of addiction: Craving. Loss of Control of amount or frequency of use. Compulsion to use. Use despite
More informationSubstance Use Disorders (SUDs) and Medication Assisted Treatment (MAT) for Opiates
Substance Use Disorders (SUDs) and Medication Assisted Treatment (MAT) for Opiates What is MAT? Medication Assisted Treatment (MAT) is the use of medications, in addition to counseling, cognitive behavioral
More informationMedication Assisted Treatment: Right for you, Right for your Recovery? Robert Matylewicz, DO, FASAM Medical Director, Clarity Way Inc.
Medication Assisted Treatment: Right for you, Right for your Recovery? Robert Matylewicz, DO, FASAM Medical Director, Clarity Way Inc. Elements Behavioral Health Diplomate, American Board of Addiction
More informationClosing the Loop in Treating Opioid Addiction:
Closing the Loop in Treating Opioid Addiction: Integrating MAT into Prison and Jail Health Systems May 9, 2018 Webinar Housekeeping All lines are muted This session will be recorded To ask a question:
More informationOpioid Use Disorder Treatment Initiation in Diverse Settings
Opioid Use Disorder Treatment Initiation in Diverse Settings Sarah Wakeman, MD, FASAM Medical Director, Mass General Substance Use Disorder Initiative Assistant Professor, Harvard Medical School Disclosures
More informationBuprenorphine is the most effective office-based treatment available for heroin and prescription opioid addiction
Buprenorphine is the most effective office-based treatment available for heroin and prescription opioid addiction The Problem The overdose death rate in Missouri and in the country has been rising for
More informationOpioid Use and Justice Involvement: Challenges in Treatment, Engagement, and Continuity
Opioid Use and Justice Involvement: Challenges in Treatment, Engagement, and Continuity Holly Hills, Ph.D. June 13, 2017 Department of Mental Health Law and Policy Overview: Persons who have not been in
More informationThe Opioid Crisis: What Can Physicians Do About It?
The Opioid Crisis: What Can Physicians Do About It? Richard S. Schottenfeld, M.D. Professor and Chair, Department of Psychiatry and Behavioral Sciences 2018 Louis J. Kolodner Memorial Lecture Disclosures
More informationQUARTERLY PROVIDER MEETING MARCH 9, 2017 SUZANNE BORYS, ED.D.
2017 State Targeted Response to the Opioid Crisis Grants QUARTERLY PROVIDER MEETING MARCH 9, 2017 SUZANNE BORYS, ED.D. H.R.6-21st Century Cures Act The 21st Century Cures Act is a United States law enacted
More informationMedication Assisted Treatment of Substance Use Disorders
3 rd Annual Challenges & Innovations in Rural Psychiatry Conference Medication Assisted Treatment of Substance Use Disorders June 22, 2016 Medication Assisted Treatment of Substance Use Disorders Richard
More informationTREATING OPIOID ADDICTION IN HOMELESS POPULATIONS
TREATING OPIOID ADDICTION IN HOMELESS POPULATIONS Challenges and Opportunities Providing Medication Assisted Treatment (Buprenorphine) August 18, 2016 SPEAKERS TODAY Nilesh Kalyanaraman, MD, Chief Health
More informationWhat Is Heroin? Examples of Opioids. What Science Says about Opioid Use Disorder and Its Treatment 6/27/2016
What Science Says about Opioid Use Disorder and Its Treatment Perilou Goddard, Ph.D. Department of Psychological Science Northern Kentucky University Examples of Opioids Agonists (activate opioid receptors)
More informationSTARTING SUBOXONE IN PRIMARY CARE
Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences STARTING SUBOXONE IN PRIMARY CARE MARK DUNCAN MD UNIVERSITY OF WASHINGTON OBJECTIVES 1. Review evidence of how to
More informationOPIOID SAFE- PRESCRIBING TRAINING IMMERSION (OSTI)
OPIOID SAFE- PRESCRIBING TRAINING IMMERSION (OSTI) Case 105- Prep Materials University of Massachusetts Medical School Opioid Conscious Curriculum Learner Prep Objectives The purpose of this prep material
More informationMedications for Opioid Use Disorder. Charles Brackett, MD, MPH General Internal Medicine, DHMC
Medications for Opioid Use Disorder Charles Brackett, MD, MPH General Internal Medicine, DHMC Opioid Related Deaths are on the Rise in the US National Vital Statistics System Mortality File Deaths are
More informationWasted AN INTRODUCTION TO SUBSTANCE ABUSE
Wasted AN INTRODUCTION TO SUBSTANCE ABUSE Dr. Brian L. Bethel Child and Family Therapist Independent Trainer and Consultant LPCC-S, LCDC III, RPT-S www.brianlbethel.com INTERPLAY COUNSELING & CONSULTING
More informationOpioid Task Force Kick-Off Meeting. February 29, 2016
Opioid Task Force Kick-Off Meeting February 29, 2016 Scope of the Opioid Problem and Data Review Olivia Kasirye, MD, MS County Public Health Officer OVERVIEW The Opioid Epidemic Opioid Task Force Development
More informationNoel Schenk MD. Davis Behavioral Health
Noel Schenk MD Davis Behavioral Health Michael Botticelli Director of National Drug Control Policy What is Addiction? Addiction is defined as a chronic, relapsing brain disease that is characterized by
More informationDivision of Mental Health and Addiction Services
Division of Mental Health and Addiction Services A DAM BUCON, LSW DMHAS Mission DMHAS, in partnership with consumers, family members, providers and other stakeholders, promotes wellness and recovery for
More informationSUBSTANCE USE DISORDER TREATMENT AND REFERRAL PROCESS
SUBSTANCE USE DISORDER TREATMENT AND REFERRAL PROCESS Presented by: John M. Connolly, Ph.D. Acting Deputy Director Los Angeles County Health Agency Department of Public Health Substance Abuse Prevention
More informationBuilding capacity for a CHC response to Ontario's Opioid Crisis
Building capacity for a CHC response to Ontario's Opioid Crisis Rob Boyd Oasis Program Director Luc Cormier, RN, MScN Community Health Nurse Sandy Hill Community Health Centre #AOHC2016 @rboyd6 @SandyHillCHC
More informationShawn A. Ryan MD, MBA President & Chief Medical Officer Board Certified, Addiction Medicine
[Patient-focused, evidence-based addiction treatment] Shawn A. Ryan MD, MBA President & Chief Medical Officer Board Certified, Addiction Medicine BrightView Health All Rights Reserved www.brightviewhealth.com
More informationChad Sabora, BS, MS, JD Missouri Network for Opiate Reform and Recovery. Drug Policy, Harm Reduction, and What s Next
Chad Sabora, BS, MS, JD Missouri Network for Opiate Reform and Recovery Drug Policy, Harm Reduction, and What s Next The start or lack thereof of Drug Policy in the United States The Harrison Narcotics
More informationStigma, Myths, Realities Limit Access to Care
Stigma, Myths, Realities Limit Access to Care MARGARET RUKSTALIS, MD Director ACGME Addiction Medicine Fellowship @ Wake Forest School of Medicine No personal or family conflicts of interest or history
More informationMedication-Assisted Treatment (MAT) Overview
Medication-Assisted Treatment (MAT) Overview 2014 Opiate Conference: Don t Get Me Started Hyatt Regency, Columbus, Ohio June 30-July 1, 2014 Christina M. Delos Reyes, MD Medical Consultant, Center for
More informationAddiction to Opioids. Marvin D. Seppala, MD Chief Medical Officer
Addiction to Opioids Marvin D. Seppala, MD Chief Medical Officer Mayo Clinic Opioid Conference: Evidence, Clinical Considerations and Best Practice Friday, September 30, 2016 26 y.o. female from South
More informationAn Alternative Payment Model Concept for Office-based Treatment of Opioid Use Disorder
An Alternative Payment Model Concept for Office-based Treatment of Opioid Use Disorder CONTENTS I. Need for an Alternative Payment Model for Opioid Use Disorder and Addiction... 2 A. Improving Services
More informationWHAT CAN I EXPECT?: DUAL SUBSTANCE USE AND MENTAL HEALTH TREATMENT FOR MILITARY POPULATIONS
WHAT CAN I EXPECT?: DUAL SUBSTANCE USE AND MENTAL HEALTH TREATMENT FOR MILITARY POPULATIONS René Lento, PhD Lauren Brenner, PhD September 25, 2018 DISCLOSURES None HOME BASE PROGRAM 3 LEARNING OBJECTIVES
More informationArwen Podesta, MD. ABIHM, ABAM, Forensic Psychiatry
The State of Medicine in Addiction Recovery Arwen Podesta, MD ABIHM, ABAM, Forensic Psychiatry www.podestawellness.com 504-252-0026 http://www.addictionpolicy.org/ Overview Addiction is a serious, chronic
More informationVivitrol Drug Court and Medication Assisted Treatment
Vivitrol Drug Court and Medication Assisted Treatment Amy Black, CNP and Judge Fred Moses Court program Self-starters Mission Statement To provide court-managed, medically assisted drug intervention treatment
More informationVivitrol/Suboxone. Comparison Study Summary
Vivitrol/Suboxone Comparison Study Summary Lee, J. D., Nunes, E. V., Novo, P., Bachrach, K., Bailey, G. L., Bhatt, S., & King, J. (2017). Comparative effectiveness of extended-release naltrexone versus
More informationMedication Assisted Treatment
Meeting the Needs of Your Clients: Building Competencies in Mental Health and Addiction Services Medication Assisted Treatment November 5, 2018 In partnership with: House Keeping Because this is a webinar,
More informationMethadone and Naltrexone ER
Methadone and Naltrexone ER Laura G. Kehoe, MD, MPH, FASAM Medical Director MGH Substance Use Disorder Bridge Clinic Assistant Professor of Medicine Harvard Medical School Disclosures Neither I nor my
More informationUnderstanding and Combating the Heroin Epidemic
Understanding and Combating the Heroin Epidemic Kelly Dunn, Ph.D. Assistant Professor; Johns Hopkins School of Medicine Department of Psychiatry and Behavioral Sciences 1 Talk Outline What is causing the
More informationHARM REDUCTION & TREATMENT. Devin Reaves MSW
HARM REDUCTION & TREATMENT Devin Reaves MSW The mission of PAHRC is to promote the health, dignity, and human rights of individuals who use drugs and communities impacted by drug use. Recognizing that
More informationChild Welfare and MOMS: Building Partnerships to Improve Care
Child Welfare and MOMS: Building Partnerships to Improve Care Goals Develop collaborative partnerships between MOMS pilot sites and child welfare agencies: Facilitate successful outcomes for clients Jointly
More informationSubstance Use Disorder Response
Substance Use Disorder Response Teresa Koeller, MD, FASAM, Medical Director, Addiction Medicine Dan Cole, CMPE, Assistant Vice President, Medical Specialties St. Elizabeth Physicians 518 Providers 372
More informationFIRST STEPS TREATMENT CENTER. David Moran CACD, LCSW, TEP Crozer-Chester Medical Center
FIRST STEPS TREATMENT CENTER David Moran CACD, LCSW, TEP Crozer-Chester Medical Center SOBERING FACTS 1. 3500 overdose deaths in Pennsylvania in 2015 2. OD rate in PA 26/100,000 OD rate in US 14.7/100,000
More informationAgenda. 1 Opioid Addiction in the United States. Evidence-based treatments for OUD. OUD Treatment: Best Practices. 4 Groups: Our Model
Agenda 1 Opioid Addiction in the United States 2 Evidence-based treatments for OUD OUD Treatment: Best Practices 4 Groups: Our Model 2 Groups is a national network of clinics providing affordable, evidencebased
More informationTHE CHRONIC DISEASE OF ADDICTION. J.A. Samander, M.D.
THE CHRONIC DISEASE OF ADDICTION J.A. Samander, M.D. OBJECTIVES Review of chronic, relapsing model of addiction Comparison with other chronic diseases Lessons from patients Addiction 24.6 million adults
More informationMass General s Substance Use Disorder Initiative
Mass General s Substance Use Disorder Initiative Martha Kane, PhD Sarah Wakeman, MD, FASAM Clinical and Medical Directors, Mass General Hospital Substance Use Disorder Initiative None Disclosures Objectives
More informationAssociate Medical Director of Addiction Medicine, Summa Physicians Inc., Akron, OH Medical Director Esper Treatment Center, Erie, PA Chief Medical
Associate Medical Director of Addiction Medicine, Summa Physicians Inc., Akron, OH Medical Director Esper Treatment Center, Erie, PA Chief Medical Officer, Interval Brotherhood Home, Akron, OH Director
More informationTreating Opioid Addiction
Treating Opioid Addiction Some people who start taking opioid pain medications eventually have serious problems with them and become addicted. Every day, 68 people die in the US from opioid overdose. More
More informationThe Opioid Crisis in Minnesota: On the Ground Approaches. Laura Palombi, PharmD, MPH, MAT, AE-C Heather Blue, PharmD, BCPS, BCGP
The Opioid Crisis in Minnesota: On the Ground Approaches Laura Palombi, PharmD, MPH, MAT, AE-C Heather Blue, PharmD, BCPS, BCGP Objectives Describe current pharmacy practices to address the opioid crisis
More informationManagement Options for Opioid Dependence:
Management Options for Opioid Dependence: Policy Implications and Recommendations Dan Ollendorf, PhD Sarah Jane Reed, MSc New England CEPAC Goal: To improve the application of evidence to guide practice
More informationRI Centers of Excellence for the
RI Centers of Excellence for the Treatment of Opioid Use Disorder COE CODAC Behavioral Healthcare Linda Hurley President/CEO 9-18-17 for the Warren Alpert Medical School of Brown University RI s Strategic
More informationMedication Assisted Treatment of an Opioid Use Disorder. J. Craig Allen, MD. Medical Director, Rushford
Medication Assisted Treatment of an Opioid Use Disorder J. Craig Allen, MD. Medical Director, Rushford Learning objectives At the conclusion of this activity, participants will be able to: Understand
More informationDiscover the Hope: Opiate Treatment and Recovery
Discover the Hope: Opiate Treatment and Recovery The Continued Struggle to Find and Implement Best Practices Ted Parran JR. M.D. FACP Carter and Isabel Wang Professor of Medical Education CWRU School of
More informationImproving the Quality of Addiction Treatment
Improving the Quality of Addiction Treatment Expanding Access to Medication-Assisted Treatment in Residential Addiction Treatment Programs Webinar sponsored by RTI International January 18, 2018 RTI International
More informationKurt Haspert, MS, CRNP University of Maryland Baltimore Washington Medical Center
Kurt Haspert, MS, CRNP University of Maryland Baltimore Washington Medical Center Data from the National Vital Statistics System Mortality The age-adjusted rate of drug overdose deaths in the United States
More information7/7/2016 Journal of the American Medical Association,
1 2 Journal of the American Medical Association, 2008 3 The Clinical Trial 152 Adolescents and Young Adults (Age 15 to 21) randomly assigned to either; 1. 2 weeks of Buprenorphine detox 2. 12 weeks of
More informationGOALS AND OBJECTIVES
SUBOXONE AND VIVITROL: ARE THERE DISPARITIES SURFACING IN MEDICATION ASSISTED TREATMENTS? P R E S E N T E D B Y D R. K I AM E M AH A N I A H & D R. M Y E C H I A M I N T E R - J O R D AN GOALS AND OBJECTIVES
More informationPublic Health Association of British Columbia
October 30 th, 2017 Open Letter to the Government of British Columbia: BC Needs an OPIOID ACTION PLAN Since April, 2016 when the epidemic of opioid overdose deaths was declared a Public Health Emergency
More informationUnderstanding Medication in Addiction Treatment for Drug Court Participants
Understanding Medication in Addiction Treatment for Drug Court Participants Introduction This pocket guide is for drug court participants who may be prescribed or considering medication as a part of addiction
More informationMedication Assisted Treatment. Karen Drexler, MD National Mental Health Program Director-Substance Use Disorders Department of Veterans Affairs
Medication Assisted Treatment Karen Drexler, MD National Mental Health Program Director-Substance Use Disorders Department of Veterans Affairs Disclosures Employed by the Department of Veterans Affairs
More informationMAT in the Corrections Setting
MEDICATION ASSISTED TREATMENT AND CORRECTIONS Frank Filippelli, DO, PhD September 2017 MAT in the Corrections Setting Who Does This Affect? What is MAT and What is the Evidence of Efficacy? Emphasis on
More information1) To understand the scope of the opioid epidemic with relation to Emergency Departments 2) To gain insight into some emerging Emergency Medicine
1) To understand the scope of the opioid epidemic with relation to Emergency Departments 2) To gain insight into some emerging Emergency Medicine solutions to the Opioid Epidemic 3) To learn about the
More informationDisclosures. Topics of today s training 4/24/2017. Evolving Treads in Medication Assisted Treatment. Christopher J Davis D.O.
Evolving Treads in Medication Assisted Treatment Christopher J Davis D.O. CAADC, FASAM Medical Director, The Ranch of Pennsylvania Medical Director, Pyramid Healthcare Diplomate of The American Board of
More informationEFFECTIVE AND RESPONSIBLE MEDICATION ASSISTED TREATMENT
WHITE PAPER EFFECTIVE AND RESPONSIBLE MEDICATION ASSISTED TREATMENT FOR OPIOID DEPENDENCE Ilana Zivkovich, LCSW, LCDC, CDWF Edward Kaufman, MD Paul Alexander, JD Kevin McCauley, MD EXECUTIVE SUMMARY Effectively
More informationPennsylvania Coordinated Medication Assisted Treatment: A Penn State and Pennsylvania Psychiatric Institute Story
Pennsylvania Coordinated Medication Assisted Treatment: A Penn State and Pennsylvania Psychiatric Institute Story Sarah Sharfstein Kawasaki, MD Director of Addictions Services, Pennsylvania Psychiatric
More informationMedication for Addiction Treatment (MAT)
SBIRT Training Screening, Brief Intervention & Referral to Treatment Medication for Addiction Treatment (MAT) The Faith & Spirituality Integrated SBIRT Network Navigating the Training Welcome! These health
More informationVivitrol Vs. Suboxone
Vivitrol Vs. Suboxone Vivitrol - Naltrexone Indicated for opiate dependence and alcohol withdrawal pure antagonist 380mg once every 4 weeks IM Peak plasma concentration in 2 hrs, followed by a second peak
More informationTreatment Approaches for Drug Addiction
Treatment Approaches for Drug Addiction NOTE: This fact sheet discusses research findings on effective treatment approaches for drug abuse and addiction. If you re seeking treatment, you can call the Substance
More informationNew Initiatives to Expand Access to Medication Assisted Treatment in NYS OASAS
New Initiatives to Expand Access to Medication Assisted Treatment in NYS OASAS Charles W. Morgan, MD, DFASAM, FAAFP Medical Director New York State Office of Alcoholism and Substance Abuse Services February
More informationMaine s Response to the Opiate Crisis. Christopher Pezzullo, DO State Health Officer Maine DHHS Maine CDC November 12, 2016
Maine s Response to the Opiate Crisis Christopher Pezzullo, DO State Health Officer Maine DHHS Maine CDC November 12, 2016 Required Disclosure Text Font typically Times New Roman at least 20 point Try
More information6/8/2018. Primary Care Providers Can Treat Opioid Use Disorder and Help End the Epidemic. Disclosures. Outline
Primary Care Providers Can Treat Opioid Use Disorder and Help End the Epidemic Adam Bisaga M.D. Division on Substance Use Disorders, Department of Psychiatry New York State Psychiatric Institute, New York,
More informationThe Importance of Psychological Treatment and Behavioral Support
The Importance of Psychological Treatment and Behavioral Support Michael W. Otto, PhD Department of Psychological and Brain Science Boston University Conflicts and Acknowledgements No industry funding
More informationDrug Abuse & Addiction Research: Progress, Priorities, & Challenges
Drug Abuse & Addiction Research: Progress, Priorities, & Challenges National Institute on Drug Abuse Bringing the full power of science to bear on drug abuse and addiction Nora D. Volkow, M.D. Director
More informationFighting Today s Opioid Epidemic
Fighting Today s Opioid Epidemic Establish in 1966 as a Public Health Department Location: Rock Falls, IL/Whiteside County Population: Whiteside County 2015--57,079 Serving Rural IL: Primarily Whiteside,
More informationDSM-5 AND ASAM CRITERIA. Presented by Jaime Goffin, LCSW
DSM-5 AND ASAM CRITERIA Presented by Jaime Goffin, LCSW MODULE 1: GOALS & OBJECTIVES What is your experience with using ASAM and DSM 5 criteria? What are your learning expectations for today? GOAL FOR
More informationTreating & Training Recovering Addicts
Treating & Training Recovering Addicts Background: Addiction Recovery Care Former prosecuting attorney and functioning alcoholic. December 11, 2006 sobriety date. August 2008 resigns as prosecutor and
More informationTreatment Alternatives for Substance Use Disorders
Treatment Alternatives for Substance Use Disorders Dean Drosnes, MD, FASAM Associate Medical Director Director, Chronic Pain and SUD Program Caron Treatment Centers 1 Disclosure The speaker has no conflict
More informationAddictions 101: Understanding, Recognizing, and Treating the Disease State!
Addictions 101: Understanding, Recognizing, and Treating the Disease State! www.overdosefreepa.org Criminal Justice Personnel Curricula Core Component 1 2014, Overdose Prevention Coalition! The OverdoseFreePA
More informationThe MGH Substance Use Disorder Initiative Sarah E. Wakeman, MD, FASAM Medical Director Assistant Professor of Medicine, Harvard Medical School
The MGH Substance Use Disorder Initiative Sarah E. Wakeman, MD, FASAM Medical Director Assistant Professor of Medicine, Harvard Medical School Disclosures Neither I nor my spouse/partner has a relevant
More informationPregnancy, MAT and Addiction
Pregnancy, MAT and Addiction Carl Christensen, MD, PhD, D-FASAM Clinical Associate Professor, OB Gyn & Psychiatry Wayne State University School of Medicine William Morrone, DO, MPH, DABAM Covenant Hospital
More informationOpioid Use Disorders &Medication Treatment
Agency medical director comments Opioid Use Disorders &Medication Treatment Charissa Fotinos, MD, MSc Deputy Chief Medical Officer Washington State Health Care Authority Learning Objectives: 1) Review
More informationMethadone and Naltrexone ER
Methadone and Naltrexone ER Laura G. Kehoe, MD, MPH, FASAM Medical Director MGH Substance Use Disorder Bridge Clinic Assistant Professor of Medicine Harvard Medical School Objectives Review Full Opioid
More informationNYS Responses to Opioid Use
NYS Responses to Opioid Use Charles W. Morgan, MD, DFASAM, FAAFP Medical Director Belinda M. Greenfield, Ph.D. Bureau Director, Adult Treatment Services NY State Opioid Treatment Authority (SOTA) Oversees
More informationASAM Criteria What it is and Why it s Important
ASAM Criteria What it is and Why it s Important ASAM Criteria: What it is and Why it s Important Webinar Wednesday, June 10, 2015 10:00 AM 11:30 AM Facilitator: Will Rhett-Mariscal, PhD, MS, Associate
More informationOvercoming the Substance Abuse Epidemic: One Member at a Time
Overcoming the Substance Abuse Epidemic: One Member at a Time Innovation and Partnerships: our keys to success Sosunmolu Shoyinka, M.D., FAPA Medical Director for Substance Use Disorders, Centene Corporation.
More informationgatewaycorrections.org TCU & Gateway Foundation 9/23/2014 Disclosures Topics Covered Opioid Use Disorders & the CJ System
Mid-America ATTC Regional Conference Medication Assisted Treatment: Promoting Tools for Successful Recovery September 23, 2014 The Use of Medication-Assisted Treatment with Justice-Involved Clients Kevin
More informationApproaches to Treatment of Youth with Opioid Addiction
Approaches to Treatment of Youth with Opioid Addiction Marc Fishman MD Mountain Manor Treatment Center Johns Hopkins University What should we do with this case? 17 M Onset prescription opioids 15, progressing
More informationCan 12 Step and Medications for Substance Use Disorders Co-Exist?
Can 12 Step and Medications for Substance Use Disorders Co-Exist? Laura G. Kehoe, MD, MPH Medical Director, Substance Use Disorders Unit Bridge Clinic Massachusetts General Hospital Overview Brief overview
More informationNew Jersey Mental Health and Addiction Providers Meeting April 26, Shereef Elnahal, M.D., M.B.A. Commissioner New Jersey Department of Health
New Jersey Mental Health and Addiction Providers Meeting April 26, 2018 Shereef Elnahal, M.D., M.B.A. Commissioner New Jersey Department of Health DOH Healthcare & Public Health Priorities Reduce disparities
More informationStrategic Plan
2017-18 Strategic Plan 1 Strategic Planning Process The Summit County Opiate Task Force has made great strides in addressing the opiate crisis in the last few years. More than 100 Summit County citizens
More informationState Opioid Response (SOR) Grant
State Opioid Response (SOR) Grant Adam Bucon, LSW DMHAS Provider Meeting September 20, 2018 Philip D. Murphy Governor Shereef M. Elnahal Commissioner Sheila Y. Oliver Lt. Governor NJ Opioid Statistics
More informationTHA Medication Safety Summit. Wesley Geminn, PharmD, BCPP
THA Medication Safety Summit Wesley Geminn, PharmD, BCPP Current Trends: Overdose Deaths in 2017 72,000 Or 197 per day 8 per hour National Opioid Overdose Statistics https://www.drugabuse.gov/related-topics/trendsstatistics/overdose-death-rates
More informationModels of good practice in drug treatment in Europe. Project group
Models of good practice in drug treatment in Europe ( moretreat 2006329 ) Project group Hamburg, London, Rome, Stockholm, Vienna, Warsaw, Zurich Project duration: 17 months from April 2006 August 2008
More informationADDRESSING THE OPIOID EPIDEMIC. Joint principles of the following organizations representing front-line physicians
ADDRESSING THE OPIOID EPIDEMIC Joint principles of the following organizations representing front-line physicians American Academy of Family Physicians American Academy of Pediatrics American College of
More information9/17/2018 MISSION IMPOSSIBLE: IF YOU CHOOSE TO ACCEPT MISSION JOIN JUSTICE LEAGUE I M POSSIBLE HEPBURN
MISSION IMPOSSIBLE: IF YOU CHOOSE TO ACCEPT MISSION JOIN JUSTICE LEAGUE I M POSSIBLE HEPBURN 1 ADDICTION PREVENTION & TREATMENT SAVES LIVES According to the Food and Drug Administration s standards for
More informationFY17 SCOPE OF WORK TEMPLATE. Name of Program/Services: Medication-Assisted Treatment: Buprenorphine
FY17 SCOPE OF WORK TEMPLATE Name of Program/Services: Medication-Assisted Treatment: Buprenorphine Procedure Code: Modification of 99212, 99213 and 99214: 99212 22 99213 22 99214 22 Definitions: Buprenorphine
More informationFinancing Factors for Implementing Medication-Assisted Treatment
Financing Factors for Implementing Medication-Assisted Treatment Jeremy Attermann, MSW, National Council for Behavioral Health Nick Szubiak, LCSW, National Council for Behavioral Health Brad DeCamp, MPA,
More informationTreatment of Youth Opioid Addiction: Approaches to a Modern Epidemic. What should we do with this case? Heroin Addiction History
Treatment of Youth Opioid Addiction: Approaches to a Modern Epidemic What should we do with this case? 17 M Onset prescription opioids 15, progressing to daily use with withdrawal within 8 months Onset
More informationLinking Opioid Treatment in Primary Care. Roxanne Lewin M.D.
Roxanne Lewin M.D. The Facts Fewer than 10 percent of individuals with an alcohol use disorder and only about 20 percent of individuals with an opioid use disorder receive specialty treatment. Many individuals
More informationChanging Course: statewide efforts to combat the opioid epidemic in California
Changing Course: statewide efforts to combat the opioid epidemic in California Kelly Pfeifer, MD kpfeifer@chcf.org April 26, 2018 State of Reform conference STAT Special Report: 52 weeks, 52 faces Obituaries
More informationHealthcare Reform, and Substance Use Disorder (SUD) Treatment
Healthcare Reform, and Substance Use Disorder (SUD) Treatment Deni Carise, Ph.D Deputy Chief Clinical Officer, CRC Health Adjunct Clinical Professor, University of Pennsylvania, School of Medicine Disclosures
More informationResponding to the Prescription Opioid and Heroin Crisis: An Epidemic of Addiction
Responding to the Prescription Opioid and Heroin Crisis: An Epidemic of Addiction Andrew Kolodny, MD Co-Director, Opioid Policy Research Collaborative Heller School for Social Policy and Management Brandeis
More informationHow serious is the opiate problem in Fairfield County?
How serious is the opiate problem in Fairfield County? The Use of Opiates in Fairfield County has increased from levels in the 1990's that were barely detectable to epidemic proportions in 2010. How serious
More information8/5/2013. MOSBIRT Annual Training The Big change in addiction medicine? Before we dive into pharmacotherapy
Medication Assisted Treatment for Substance Abuse in Primary Care Dan Vinson August 1, 2013 1 The Big change in addiction medicine? These diseases are rapidly becoming medical diseases. Done are the days
More information